Evidence map›Paper›PMID 27014633›Full record

ArticleFrontiers in oncology2016

Influence of Dose Rate on the Cellular Response to Low- and High-LET Radiations.

Anne-Sophie Wozny, Gersende Alphonse, Priscillia Battiston-Montagne, Stéphanie Simonet, Delphine Poncet, Etienne Testa, Jean-Baptiste Guy, Chloé Rancoule, Nicolas Magné, Michael Beuve and 1 more

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Relative Efficacy ofMolecular imaging and radionuclide therapy · 2022
    Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Anne-Sophie WoznyUMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Université Claude Bernard Lyon 1, Oullins, France; Centre Hospitalier Lyon-Sud, Hospices-Civils-de-Lyon, Pierre-Bénite, France.
Gersende AlphonseUMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Université Claude Bernard Lyon 1, Oullins, France; Centre Hospitalier Lyon-Sud, Hospices-Civils-de-Lyon, Pierre-Bénite, France.
Priscillia Battiston-MontagneUMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Université Claude Bernard Lyon 1 , Oullins , France.
Stéphanie SimonetUMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Université Claude Bernard Lyon 1 , Oullins , France.
Delphine PoncetUMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Université Claude Bernard Lyon 1, Oullins, France; Centre Hospitalier Lyon-Sud, Hospices-Civils-de-Lyon, Pierre-Bénite, France.
Etienne TestaIPNL-LIRIS-CNRS-IN2P3 , Villeurbanne , France.
Jean-Baptiste GuyUMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Université Claude Bernard Lyon 1, Oullins, France; Département de Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirth, St-Priest-en-Jarez, France.
Chloé RancouleDépartement de Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirth , St-Priest-en-Jarez , France.
Nicolas MagnéUMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Université Claude Bernard Lyon 1, Oullins, France; Département de Radiothérapie, Institut de Cancérologie de la Loire Lucien Neuwirth, St-Priest-en-Jarez, France.
Michael BeuveIPNL-LIRIS-CNRS-IN2P3 , Villeurbanne , France.
Claire Rodriguez-LafrasseUMR/CNRS 5822, Laboratoire de Radiobiologie Cellulaire et Moléculaire, Université Claude Bernard Lyon 1, Oullins, France; Centre Hospitalier Lyon-Sud, Hospices-Civils-de-Lyon, Pierre-Bénite, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nowadays, head and neck squamous cell carcinoma (HNSCC) treatment failure is mostly explained by locoregional progression or intrinsic radioresistance. Radiotherapy (RT) has recently evolved with the emergence of heavy ion radiations or new fractionation schemes of photon therapy, which modify the dose rate of treatment delivery. The aim of the present study was then to evaluate the in vitro influence of a dose rate variation during conventional RT or carbon ion hadrontherapy treatment in order to improve the therapeutic care of patient. In this regard, two HNSCC cell lines were irradiated with photons or 72 MeV/n carbon ions at a dose rate of 0.5, 2, or 10 Gy/min. For both radiosensitive and radioresistant cells, the change in dose rate significantly affected cell survival in response to photon exposure. This variation of radiosensitivity was associated with the number of initial and residual DNA double-strand breaks (DSBs). By contrast, the dose rate change did not affect neither cell survival nor the residual DNA DSBs after carbon ion irradiation. As a result, the relative biological efficiency at 10% survival increased when the dose rate decreased. In conclusion, in the RT treatment of HNSCC, it is advised to remain very careful when modifying the classical schemes toward altered fractionation. At the opposite, as the dose rate does not seem to have any effects after carbon ion exposure, there is less need to adapt hadrontherapy treatment planning during active system irradiation.

Indexed as

carbon ionsDNA double-strand breaksdose ratehead and neck squamous cell carcinomahigh- and low-LET irradiationsphotons

Identifiers

PMID27014633
PMCPMC4790194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.